Keywords: Breast Neoplasms, Diagnosis, Radionuclide Imaging, Radiopharmaceuticals, Antineoplastic Agent, Epirubicin, Etoposide, Glycoprotein P, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Mitomycin C, Protein Bcl 2, Tracer, Apoptosis, Breast Cancer, Cancer Chemotherapy, Cancer Diagnosis, Cancer Radiotherapy, Clinical Trial, Drug Clearance, Drug Response, Drug Uptake, Functional Assessment, Human, Lung Cancer, Lymphoma, Meta Analysis, Multidrug Resistance, Phenotype, Prediction, Prognosis, Protein Expression, Protein Interaction, Review, Sarcoma, Scintiscanning, Metabolic Clearance Rate, Technetium Tc 99m Sestamibi, Treatment Outcome,
Affiliations: *** IBB - CNR ***
Center for Nuclear Medicine, Consiglio Nazionale dell Ricerche, Federico II University, Via S. Pansini 5, 80131 Naples, Italy
Dept. of Biomorphol. and Funct. Sci., Federico II University, Via S. Pansini 5, 80131 Naples, Italy
Piwnica-Worms, D., Kronauge, J.F., Chiu, M.L., Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence (1990) Circulation, 82, pp. 1826-1838
Delmon-Moingeon, L.I., Piwnica-Worms, D., Van Den Abbeele, A.D., Holman, B.L., Davison, A., Jones, A.G., Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro (1990) Cancer Res, 50, pp. 2198-2202
Bradshaw, D.M., Arceri, R.J., Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance (1998) J Clin Oncol, 16, pp. 3674-3690
Ballinger, J.R., Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein (2001) Cancer Biother Radiopharm, 16, pp. 1-7
Del Vecchio, S., Ciarmiello, A., Salvatore, M., Scintigraphic detection of multidrug resistance in cancer (2000) Cancer Biother Radiopharm, 15, pp. 327-337
Dimitrakopoulou-Strauss, A., Strauss, L.G., Goldschmidt, H., Lorenz, W.J., Maier-Borst, W., Van Kaick, G., Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas (1995) Eur J Nucl Med, 22, pp. 434-442
Kapucu, L.O., Akyuz, C., Vural, G., Oguz, A., Atasever, T., Buyukpamukcu, M., Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi (1997) J Nucl Med, 38, pp. 243-247
Kao, C.H., Tsai, S.C., Wang, J.J., Ho, Y.J., Ho, S.T., Changlai, S.P., Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors (2001) Br J Haematol, 113, pp. 369-374
Bom, H.S., Kim, Y.C., Song, H.C., Min, J.J., Kim, J.Y., Park, K.O., Technetium-99m-MIBI uptake in small cell lung cancer (1998) J Nucl Med, 39, pp. 91-94
Yamamoto, Y., Nishiyama, Y., Satoh, K., Takashima, H., Ohkawa, M., Fujita, J., Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer (1998) J Nucl Med, 39, pp. 1626-1629
Kao, C.H., Hsieh, J.F., Tsai, S.C., Ho, Y.J., Lee, J.K., Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography (2000) Clin Cancer Res, 6, pp. 820-824
Trock, B.J., Leonessa, F., Clarke, R., Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance (1997) J Natl Cancer Inst, 89, pp. 917-931
Moretti, J.L., Azaloux, H., Boisseron, D., Kouyoumdjian, J.C., Vilcoq, J., Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression (1996) Eur J Nucl Med, 23, pp. 980-986
Kostakoglu, L., Elahi, N., Kiratli, P., Ruacan, S., Sayek, I., Baltali, E., Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors (1997) J Nucl Med, 38, pp. 1003-1008
Del Vecchio, S.D., Ciarmiello, A., Potena, M.I., Carriero, M.V., Mainolfi, C., Botti, G., In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Ciarmiello, A., Del Vecchio, S., Silvestro, P., Potena, M.I., Carriero, M.V., Thomas, R., Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer (1998) J Clin Oncol, 16, pp. 1677-1683
Takamura, Y., Miyoshi, Y., Taguchi, T., Noguchi, S., Prediction of chemotherapeutic response by technetium 99m-MIBI scintigraphy in breast carcinoma patients (2001) Cancer, 92, pp. 232-239
Sasaki, M., Kuwabara, Y., Ichiya, Y., Yoshida, T., Nakagawa, M., Soeda, H., Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT (1999) J Nucl Med, 40, pp. 1778-1783
Nishiyama, Y., Yamamoto, Y., Fukunaga, K., Kiuchi, T., Satoh, K., Takashima, H., Evaluation of radiotherapeutic response in non-small cell lung cancer patients by technetium-99m MIBI and thallium-201 chloride SPET (2000) Eur J Nucl Med, 27, pp. 536-541
Desagher, S., Martinou, J.C., Mitochondria as the central control point of apoptosis (2000) Trends Cell Biol, 10, pp. 369-377
Korsmeyer, S.J., BCL-2 gene family and the regulation of programmed cell death (1999) Cancer Res, 59, pp. 1693s-1700s
Del Vecchio, S., Zannetti, A., Ciarmiello, A., Aloj, L., Fonti, R., Caracò, C., 99mTc-MIBI uptake and Bcl-2 overexpression in untreated breast cancer patients (2001) Eur J Nucl Med, 28, p. 1120
Eary, J. F., Krohn, K. A., Positron emission tomography: Imaging tumor response (2000) Eur J Nucl Med, 27, pp. 1737-173
Bradshaw, D. M., Arceri, R. J., Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance (1998) J Clin Oncol, 16, pp. 3674-3690
Ballinger, J. R., Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein (2001) Cancer Biother Radiopharm, 16, pp. 1-7
Kapucu, L. O., Akyuz, C., Vural, G., Oguz, A., Atasever, T., Buyukpamukcu, M., Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi (1997) J Nucl Med, 38, pp. 243-247
Kao, C. H., Tsai, S. C., Wang, J. J., Ho, Y. J., Ho, S. T., Changlai, S. P., Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors (2001) Br J Haematol, 113, pp. 369-374
Bom, H. S., Kim, Y. C., Song, H. C., Min, J. J., Kim, J. Y., Park, K. O., Technetium-99m-MIBI uptake in small cell lung cancer (1998) J Nucl Med, 39, pp. 91-94
Kao, C. H., Hsieh, J. F., Tsai, S. C., Ho, Y. J., Lee, J. K., Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography (2000) Clin Cancer Res, 6, pp. 820-824
Trock, B. J., Leonessa, F., Clarke, R., Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance (1997) J Natl Cancer Inst, 89, pp. 917-931
Moretti, J. L., Azaloux, H., Boisseron, D., Kouyoumdjian, J. C., Vilcoq, J., Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression (1996) Eur J Nucl Med, 23, pp. 980-986
Del Vecchio, S. D., Ciarmiello, A., Potena, M. I., Carriero, M. V., Mainolfi, C., Botti, G., In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Korsmeyer, S. J., BCL-2 gene family and the regulation of programmed cell death (1999) Cancer Res, 59, pp. 1693s-1700s
MIBI as prognostic factor in breast cancer
Evaluation of treatment response is of primary importance in the management of patients with cancer. Both positron- and γ-emitting compounds have been used to monitor changes in tumor metabolism or viability after therapy. The use of 99mTc-labeled lipophilic cations raised the possibility to predict the tumor response to treatment and to identify patients who will become refractory to subsequent therapy. In particular, many studies have shown the prognostic value of 99mTc-MIBI scan in different types of malignancy including breast and lung cancer, lymphoma and sarcoma. The ability of 99mTc-MIBI to interact with P-glycoprotein, allowing the functional assessment of the multidrug resistant phenotype, is one of the mechanisms underlying its prognostic value. Additional mechanisms of cell resistance, mainly involving alterations of apoptosis, may affect 99mTc-MIBI uptake in tumors. Therefore, either an enhanced tracer clearance or a reduced early uptake of 99mTc-MIBI indicate a poor response to therapy. In both cases, 99mTc-MIBI scan may ensure that the further management strategy will be effective in individual cancer patients.
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(289 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote